Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (503) 503
Newspaper Article (22) 22
Book Chapter (13) 13
Book / eBook (6) 6
Book Review (1) 1
Magazine Article (1) 1
Patent (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (231) 231
humans (222) 222
life sciences & biomedicine (222) 222
male (134) 134
female (126) 126
gastroenterology & hepatology (121) 121
middle aged (103) 103
adult (99) 99
hepatitis c (99) 99
hepatitis c, chronic - drug therapy (98) 98
antiviral agents - therapeutic use (97) 97
gastroenterology and hepatology (86) 86
biological and medical sciences (85) 85
medical sciences (83) 83
hepatitis c virus (76) 76
hepacivirus - genetics (74) 74
treatment outcome (71) 71
infectious diseases (70) 70
drug therapy, combination (67) 67
genotype (59) 59
abridged index medicus (57) 57
hepatitis (57) 57
aged (56) 56
antiviral agents (55) 55
health aspects (54) 54
hepatitis c, chronic - virology (53) 53
viral diseases (52) 52
human viral diseases (51) 51
ribavirin - therapeutic use (49) 49
care and treatment (48) 48
antiviral agents - adverse effects (46) 46
interferon (45) 45
viral hepatitis (45) 45
antiviral agents - administration & dosage (37) 37
drug therapy (37) 37
interferon-alpha - therapeutic use (37) 37
ribavirin (37) 37
viral load (31) 31
infections (30) 30
polyethylene glycols - therapeutic use (30) 30
general & internal medicine (29) 29
hepacivirus - drug effects (29) 29
medicine, general & internal (29) 29
virology (29) 29
biological response modifiers (28) 28
liver (27) 27
young adult (27) 27
genotype & phenotype (26) 26
ribavirin - administration & dosage (26) 26
rna, viral - blood (26) 26
analysis (25) 25
interferon-alpha - administration & dosage (25) 25
pharmacology. drug treatments (25) 25
recombinant proteins (25) 25
research (25) 25
sofosbuvir (25) 25
clinical trials (24) 24
genetic aspects (24) 24
hepatitis b (24) 24
patients (24) 24
immunology (23) 23
medical colleges (23) 23
ribavirin - adverse effects (23) 23
genotypes (22) 22
hepatitis c - drug therapy (22) 22
virus diseases (22) 22
antibiotics. antiinfectious agents. antiparasitic agents (21) 21
risk factors (21) 21
adolescent (20) 20
hepatology (20) 20
gastroenterology. liver. pancreas. abdomen (19) 19
oligopeptides - therapeutic use (19) 19
polyethylene glycols - administration & dosage (19) 19
cirrhosis (18) 18
diagnosis (18) 18
interferon-alpha - adverse effects (18) 18
medical research (18) 18
microbiology (18) 18
protease inhibitors (18) 18
recombinant proteins - therapeutic use (18) 18
chronic infection (17) 17
drug administration schedule (17) 17
hepatitis b, chronic - drug therapy (17) 17
liver cirrhosis (17) 17
liver diseases (17) 17
recombinant proteins - administration & dosage (17) 17
viral nonstructural proteins - antagonists & inhibitors (17) 17
aged, 80 and over (16) 16
hepacivirus - isolation & purification (16) 16
viruses (16) 16
hepatitis c, chronic - complications (15) 15
liver cirrhosis - virology (15) 15
polyethylene glycols - adverse effects (15) 15
proline - analogs & derivatives (15) 15
uridine monophosphate - analogs & derivatives (15) 15
animals (14) 14
double-blind method (14) 14
hiv (14) 14
recurrence (14) 14
retrospective studies (14) 14
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
by Kowdley, Kris V, Dr and Lawitz, Eric, MD and Crespo, Israel, MD and Hassanein, Tarek, MD and Davis, Mitchell N, MD and DeMicco, Michael, MD and Bernstein, David E, MD and Afdhal, Nezam, MD and Vierling, John M, MD and Gordon, Stuart C, MD and Anderson, Jane K, PhD and Hyland, Robert H, DPhil and Dvory-Sobol, Hadas, PhD and An, Di, PhD and Hindes, Robert G, MD and Albanis, Efsevia, MD and Symonds, William T, PharmD and Berrey, M Michelle, MD and Nelson, David R, MD and Jacobson, Ira M, MD
The Lancet (British edition), ISSN 0140-6736, 2013, Volume 381, Issue 9883, pp. 2100 - 2107
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | General aspects | Viral hepatitis | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Uridine Monophosphate - administration & dosage | Puerto Rico | United States | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Ribavirin - administration & dosage | Uridine Monophosphate - analogs & derivatives | Female | Drug Therapy, Combination | Hepatitis C, Chronic - genetics | Sofosbuvir | Complications and side effects | Peginterferon alfa-2a | Dosage and administration | Research | Hepatitis C | Drug therapy | Ribavirin | Hepatitis | Genotype & phenotype | Infections | Liver cirrhosis | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
by Lawitz, Eric, Prof and Sulkowski, Mark S, Prof and Ghalib, Reem, MD and Rodriguez-Torres, Maribel, MD and Younossi, Zobair M, Prof and Corregidor, Ana, MD and DeJesus, Edwin, MD and Pearlman, Brian, Prof and Rabinovitz, Mordechai, Prof and Gitlin, Norman, MD and Lim, Joseph K, MD and Pockros, Paul J, MD and Scott, John D, MD and Fevery, Bart, MSc and Lambrecht, Tom, MSc and Ouwerkerk-Mahadevan, Sivi, PhD and Callewaert, Katleen, MSc and Symonds, William T, PharmD and Picchio, Gaston, PhD and Lindsay, Karen L, MD and Beumont, Maria, MD and Jacobson, Ira M, Prof
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | General aspects | Viral hepatitis | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Simeprevir | Confidence Intervals | Follow-Up Studies | Humans | Middle Aged | Hepacivirus - genetics | Male | Reference Values | Polyethylene Glycols - therapeutic use | Dose-Response Relationship, Drug | Adult | Female | Drug Therapy, Combination | Liver Function Tests | Severity of Illness Index | Drug Administration Schedule | Risk Assessment | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Sulfonamides - therapeutic use | Heterocyclic Compounds, 3-Ring - therapeutic use | Uridine Monophosphate - analogs & derivatives | Hepatitis C, Chronic - genetics | Sofosbuvir | Hepatitis | Genotype & phenotype | Liver diseases | Biopsy | Infections | Drug therapy | Liver cirrhosis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
by Kwo, Paul Y, Dr and Lawitz, Eric J, MD and McCone, Jonathan, MD and Schiff, Eugene R, Prof and Vierling, John M, Prof and Pound, David, MD and Davis, Mitchell N, DO and Galati, Joseph S, MD and Gordon, Stuart C, MD and Ravendhran, Natarajan, MD and Rossaro, Lorenzo, Prof and Anderson, Frank H, MD and Jacobson, Ira M, Prof and Rubin, Raymond, MD and Koury, Kenneth, PhD and Pedicone, Lisa D, PhD and Brass, Clifford A, MD and Chaudhri, Eirum, MD and Albrecht, Janice K, PhD and on behalf of the SPRINT-1 investigators and SPRINT-1 investigators
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9742, pp. 705 - 716
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Humans | Middle Aged | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Male | Recombinant Proteins | Hepatitis C, Chronic - drug therapy | Polyethylene Glycols - therapeutic use | Viral Load | Proline - therapeutic use | Adult | Female | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Peginterferon alfa-2b | Boceprevir | Dosage and administration | Hepatitis C | Drug therapy | Ribavirin | Data collection | Hepatitis | Genotype & phenotype | Clinical medicine | Hemophilia | Committees | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
by Marcellin, Patrick, Prof and Gane, Edward, Prof and Buti, Maria, Prof and Afdhal, Nezam, Prof and Sievert, William, Prof and Jacobson, Ira M, Prof and Washington, Mary Kay, Prof and Germanidis, George, Prof and Flaherty, John F, PharmD and Schall, Raul Aguilar, PhD and Bornstein, Jeffrey D, MD and Kitrinos, Kathryn M, PhD and Subramanian, G Mani, MD and McHutchison, John G, MD and Heathcote, E Jenny, Prof
The Lancet (British edition), ISSN 0140-6736, 2013, Volume 381, Issue 9865, pp. 468 - 475
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | General aspects | Viral hepatitis | Infectious diseases | Liver. Biliary tract. Portal circulation. Exocrine pancreas | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Other diseases. Semiology | Immunohistochemistry | Severity of Illness Index | Adenine - analogs & derivatives | Double-Blind Method | Drug Administration Schedule | Follow-Up Studies | Humans | Middle Aged | Safety Management | Male | Treatment Outcome | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - administration & dosage | Dose-Response Relationship, Drug | Tenofovir | Hepatitis B virus - drug effects | Organophosphonates - administration & dosage | Hepatitis B, Chronic - drug therapy | Time Factors | Adult | Female | Biopsy, Needle | Hepatitis B, Chronic - pathology | Complications and side effects | Dosage and administration | Research | Drug therapy | Liver cirrhosis | Risk factors | Hepatitis B | Hepatitis | Liver cancer | Consent | Mortality | Infections | Histology | Deoxyribonucleic acid--DNA | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
by Jacobson, Ira M, Prof and Dore, Gregory J, Prof and Foster, Graham R, Prof and Fried, Michael W, Prof and Radu, Monica, MD and Rafalsky, Vladimir V, Prof and Moroz, Larysa, Prof and Craxi, Antonio, Prof and Peeters, Monika, MSc and Lenz, Oliver, PhD and Ouwerkerk-Mahadevan, Sivi, PhD and De La Rosa, Guy, MD and Kalmeijer, Ronald, MD and Scott, Jane, PhD and Sinha, Rekha, PhD and Beumont-Mauviel, Maria, PhD
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9941, pp. 403 - 413
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Simeprevir | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Hepacivirus - genetics | Genotype | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Ribavirin - administration & dosage | Sulfonamides - adverse effects | Adult | Female | Drug Therapy, Combination | Sulfonamides - administration & dosage | Patient outcomes | Interferon alpha | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Methods | Analysis | Clinical trials | Genetic aspects | Interferon | Biological response modifiers | Hepatitis C virus | Health aspects | Hepatitis | Genotype & phenotype | Infections | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis?
by Jacobson, Ira M
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 10/2018, Volume 155, Issue 4, pp. 969 - 971
Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
by Jacobson, Ira M and Gordon, Stuart C and Kowdley, Kris V and Yoshida, Eric M and Rodriguez-Torres, Maribel and Sulkowski, Mark S and Shiffman, Mitchell L and Lawitz, Eric and Everson, Gregory and Bennett, Michael and Schiff, Eugene and Al-Assi, M. Tarek and Subramanian, G. Mani and An, Di and Lin, Ming and McNally, John and Brainard, Diana and Symonds, William T and McHutchison, John G and Patel, Keyur and Feld, Jordan and Pianko, Stephen and Nelson, David R and POSITRON Study and FUSION Study
The New England journal of medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 20, pp. 1867 - 1877
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | General aspects | Viral hepatitis | Infectious diseases | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Antiviral Agents - therapeutic use | Humans | Middle Aged | Ribavirin - therapeutic use | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Genotype | Logistic Models | Male | RNA, Viral - blood | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Young Adult | Liver Cirrhosis - virology | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adult | Female | Aged | Uridine Monophosphate - adverse effects | Drug Therapy, Combination | Sofosbuvir | Uridine Monophosphate - therapeutic use | Antiviral agents | Care and treatment | Causes of | Dosage and administration | Research | Hepatitis C | Mental illness | Headache | Clinical trials | Chronic infection | Fatigue | Infections | Nausea | Patients | Ribavirin | Cirrhosis | Sleep disorders | Genotype & phenotype | Hepatitis | Interferon | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
by Locke, Frederick L and Ghobadi, Armin and Jacobson, Caron A and Miklos, David B and Lekakis, Lazaros J and Oluwole, Olalekan O and Lin, Yi and Braunschweig, Ira and Hill, Brian T and Timmerman, John M and Deol, Abhinav and Reagan, Patrick M and Stiff, Patrick and Flinn, Ian W and Farooq, Umar and Goy, Andre and McSweeney, Peter A and Munoz, Javier and Siddiqi, Tanya and Chavez, Julio C and Herrera, Alex F and Bartlett, Nancy L and Wiezorek, Jeffrey S and Navale, Lynn and Xue, Allen and Jiang, Yizhou and Bot, Adrian and Rossi, John M and Kim, Jenny J and Go, William Y and Neelapu, Sattva S
The lancet oncology, ISSN 1470-2045, 01/2019, Volume 20, Issue 1, pp. 31 - 42
Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclophosphamide - administration & dosage | Lymphoma, Follicular - therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Lymphoma, Large B-Cell, Diffuse - therapy | Antigens, CD19 - adverse effects | Antigens, CD19 - therapeutic use | Adult | Female | Immunotherapy, Adoptive - adverse effects | Lymphoma, Follicular - pathology | Vidarabine - adverse effects | Antigens, CD19 - administration & dosage | Lymphoma, Follicular - mortality | Treatment Outcome | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Lymphoma, Large B-Cell, Diffuse - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Vidarabine - administration & dosage | Analysis | Lymphomas | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection
by Vermehren, Johannes and Park, James S and Jacobson, Ira M and Zeuzem, Stefan
Journal of hepatology, ISSN 0168-8278, 11/2018, Volume 69, Issue 5, pp. 1178 - 1187
Pibrentasvir | Glecaprevir | Velpatasvir | Hepatitis C Virus infection | Voxilaprevir | Direct-acting antivirals | Sofosbuviri | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Hepatitis | Chronic infection | Infections | Hepatitis C | Patients | Clinical outcomes | Genotypes | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights